Novo Nordisk Announces $12B Manufacturing Expansion to Meet GLP-1 Demand

Novo Nordisk has announced a landmark $12 billion manufacturing expansion, the largest capital investment in the company's 102-year history, aimed at doubling global peptide production capacity by 2028. The announcement comes amid continued global shortages of GLP-1 receptor agonists that have plagued patients and healthcare providers since 2023.

The investment will fund three new manufacturing facilities in Denmark, the United States, and Brazil, plus expansion of existing sites in France and China. The company stated that current capacity cannot keep pace with demand that has grown more than 300% since Wegovy's obesity indication received FDA approval in 2021.

Addressing the Supply Crisis

The announcement follows months of ongoing supply constraints that have forced patients to cycle between medications or pay premium prices in gray markets. In February 2026, the FDA added semaglutide to its drug shortage database, a designation that remains in effect despite production increases.

"We recognize that millions of patients depend on these medicines, and we are committed to solving the supply challenge as quickly as possible," said Novo Nordisk CEO Lars Fruergaard Jørgensen in a press conference. "This investment represents our belief in the long-term demand for peptide therapeutics."

Industry Ripple Effects

The expansion signals confidence in continued GLP-1 market growth, which analysts now project could exceed $150 billion annually by 2030. Competitors including Eli Lilly, Pfizer, and emerging biotech players are also ramping up production, creating a capital spending race across the industry.

The investment may also have geopolitical implications, as nations seek to reduce dependence on imported peptide Active Pharmaceutical Ingredients (APIs), particularly from China where the majority of GLP-1 raw materials are currently manufactured.

FAQ

q: How will this expansion affect patient access? a: The new facilities are expected to come online in phases beginning in late 2027, with full capacity reached by 2028. Until then, supply constraints are likely to continue, particularly for higher-dose formulations used for obesity treatment.

q: Why is Novo Nordisk investing so heavily now? a: The company faces competitive pressure from Eli Lilly's tirzepatide (Mounjaro/Zepbound) and upcoming GLP-1/GIP dual agonists from multiple competitors. Securing supply advantage is seen as critical to maintaining market leadership.

q: Will the expansion include API manufacturing? a: Yes. Novo Nordisk has indicated it will bring more of its peptide API production in-house, reducing reliance on contract manufacturers and Chinese suppliers amid ongoing geopolitical tensions.